{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:56:08Z","timestamp":1793822168721,"version":"4.6.1"},"reference-count":314,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jaad.2024.11.071","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T16:43:33Z","timestamp":1735058613000},"page":"825-852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6506-9568","authenticated-orcid":false,"given":"Raed","family":"Alhusayen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5916-8201","authenticated-orcid":false,"given":"Serena","family":"Dienes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alikhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Aleshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Bahashwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Daveluy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Gulliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarannum","family":"Jaleel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joslyn","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joi","family":"Lenczowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Lev-Tov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Lowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lara-Corrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Okun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Orenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Poelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Resnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathryn","family":"Sibbald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Mang","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zaenglein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Veillette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley B.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5 Suppl 1","key":"10.1016\/j.jaad.2024.11.071_bib1","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jaad.2015.07.052","article-title":"Hidradenitis suppurativa: epidemiology and scope of the problem","volume":"73","author":"Jemec","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"7650","key":"10.1016\/j.jaad.2024.11.071_bib2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7652","key":"10.1016\/j.jaad.2024.11.071_bib3","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.jaad.2024.11.071_bib4","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/jdv.15709","article-title":"European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period","volume":"33","author":"Vestergaard","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0146-6380(85)90054-3","article-title":"Humic substances, a possible source of environmental goitrogens","volume":"8","author":"Cooksey","year":"1985","journal-title":"Org Geochem"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/15287399209531686","article-title":"Antithyroid effects of coal-derived pollutants","volume":"37","author":"Lindsay","year":"1992","journal-title":"J Toxicol Environ Health"},{"issue":"32","key":"10.1016\/j.jaad.2024.11.071_bib7","doi-asserted-by":"crossref","first-page":"9668","DOI":"10.1021\/bi00198a036","article-title":"Mechanism-based inactivation of lactoperoxidase and thyroid peroxidase by resorcinol derivatives","volume":"33","author":"Divi","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.jaad.2024.11.071_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.yrtph.2016.06.019","article-title":"A comparison of potency differences among thyroid peroxidase (TPO) inhibitors to induce developmental toxicity and other thyroid gland-linked toxicities in humans and rats","volume":"80","author":"Motonaga","year":"2016","journal-title":"Regul Toxicol Pharmacol"},{"issue":"1-2","key":"10.1016\/j.jaad.2024.11.071_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tox.2012.05.023","article-title":"Developmental triclosan exposure decreases maternal, fetal, and early neonatal thyroxine: a dynamic and kinetic evaluation of a putative mode-of-action","volume":"300","author":"Paul","year":"2012","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/toxsci\/kfp271","article-title":"Short-term exposure to triclosan decreases thyroxine in\u00a0vivo via upregulation of hepatic catabolism in young long-evans rats","volume":"113","author":"Paul","year":"2010","journal-title":"Toxicol Sci"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1742-7843.2009.00455.x","article-title":"Human exposure to triclosan via toothpaste does not change CYP3A4 activity or plasma concentrations of thyroid hormones","volume":"105","author":"Allmyr","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jaad.2024.11.071_bib12","article-title":"The influence of triclosan on the thyroid hormone system in humans - a systematic review","volume":"13","author":"Homburg","year":"2022","journal-title":"Front Endocrinol Lausanne"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/ajcn\/42.5.815","article-title":"Zinc supplementation during pregnancy in low income teenagers of Mexican descent: effects on selected blood constituents and on progress and outcome of pregnancy","volume":"42","author":"Hunt","year":"1985","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"10.1016\/j.jaad.2024.11.071_bib14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3109\/00016349609065735","article-title":"Zinc supplementation during pregnancy: a double blind randomised controlled trial","volume":"75","author":"Jonsson","year":"1996","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"6703","key":"10.1016\/j.jaad.2024.11.071_bib15","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/bmj.299.6703.826","article-title":"Zinc supplementation during pregnancy: a double blind randomised controlled trial","volume":"299","author":"Mahomed","year":"1989","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib16","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ajcn\/50.5.945","article-title":"Adolescent pregnancy: associations among body weight, zinc nutriture, and pregnancy outcome","volume":"50","author":"Cherry","year":"1989","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/ajcn\/71.1.114","article-title":"A randomized, placebo-controlled trial of the effect of zinc supplementation during pregnancy outcome in Bangladeshi urban poor","volume":"71","author":"Osendarp","year":"2000","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40257-018-0374-5","article-title":"Serum zinc levels in hidradenitis suppurativa: a case-control study","volume":"19","author":"Poveda","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"9362","key":"10.1016\/j.jaad.2024.11.071_bib20","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(03)12823-1","article-title":"Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial","volume":"361","author":"Ugwumadu","year":"2003","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/bcp.12910","article-title":"Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women","volume":"82","author":"Moore","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.olq.0000187226.32145.ea","article-title":"An observational cohort study of Chlamydia trachomatis treatment in pregnancy","volume":"33","author":"Rahangdale","year":"2006","journal-title":"Sex Transm Dis"},{"issue":"7","key":"10.1016\/j.jaad.2024.11.071_bib23","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jsps.2017.01.005","article-title":"Adverse drug reactions in high-risk pregnant women: a prospective study","volume":"25","author":"de Oliveira-Filho","year":"2017","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.jaad.2024.11.071_bib24","series-title":"Obstetrics Handbook for Maternal Health","author":"Nanavati","year":"1994"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/centers for disease control and prevention\/infectious diseases Society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaad.2024.11.071_bib26","series-title":"Treatment of Tuberculosis Guidelines","year":"2010"},{"key":"10.1016\/j.jaad.2024.11.071_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5505\/respircase.2021.38980","article-title":"COVID-19 during pregnancy: the role of the mother and baby in every decision","volume":"10","author":"\u00c7etin","year":"2021","journal-title":"Respir Case Rep"},{"key":"10.1016\/j.jaad.2024.11.071_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2021.e01107","article-title":"Disseminated herpes simplex virus 2 as a complication of pregnancy","volume":"24","author":"Bougioukas","year":"2021","journal-title":"IDCases"},{"key":"10.1016\/j.jaad.2024.11.071_bib29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s13256-023-04180-w","article-title":"Lethal pulmonary embolism in a pregnant woman with severe acute respiratory syndrome coronavirus-2 receiving prophylactic anticoagulation: a case report","volume":"17","author":"Perfilyeva","year":"2023","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.jaad.2024.11.071_bib30","series-title":"Ertapenem (Package Insert)","first-page":"e01107","year":"2010"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.diabres.2012.09.031","article-title":"Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial","volume":"98","author":"Niromanesh","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib32","article-title":"Could metformin manage gestational diabetes mellitus instead of insulin?","volume":"2016","author":"Saleh","year":"2016","journal-title":"Int J Reprod Med"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib33","first-page":"327","article-title":"Comparison of newborn outcomes in women with gestational diabetes mellitus treated with metformin or insulin: a randomised blinded trial","volume":"4","author":"Mesdaghinia","year":"2013","journal-title":"Int J Prev Med"},{"issue":"19","key":"10.1016\/j.jaad.2024.11.071_bib34","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMoa0707193","article-title":"Metformin versus insulin for the treatment of gestational diabetes","volume":"358","author":"Rowan","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib35","first-page":"970","article-title":"Neonatal outcomes in women with gestational diabetes mellitus treated with metformin in compare with insulin: a randomized clinical trial","volume":"19","author":"Ruholamin","year":"2014","journal-title":"J Res Med Sci"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib36","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jog.12950","article-title":"Identification of metformin poor responders, requiring supplemental insulin, during randomization of metformin versus insulin for the control of gestational diabetes mellitus","volume":"42","author":"Ashoush","year":"2016","journal-title":"J Obstet Gynaecol Res"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/dom.12017","article-title":"Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin","volume":"15","author":"Tertti","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib38","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(20)30310-7","article-title":"Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial","volume":"8","author":"Feig","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib39","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00404-013-3090-7","article-title":"The role of adding metformin in insulin-resistant diabetic pregnant women: a randomized controlled trial","volume":"289","author":"Ibrahim","year":"2014","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib40","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1509819","article-title":"Metformin versus placebo in obese pregnant women without diabetes mellitus","volume":"374","author":"Syngelaki","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaad.2024.11.071_bib41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.1464-5491.2000.00314.x","article-title":"Oral hypoglycaemic agents in 118 diabetic pregnancies","volume":"17","author":"Hellmuth","year":"2000","journal-title":"Diabet Med J Br Diabet Assoc"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib42","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1210\/jcem.87.2.8207","article-title":"Effects of metformin on early pregnancy loss in the polycystic ovary syndrome","volume":"87","author":"Jakubowicz","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib43","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0015-0282(01)03202-2","article-title":"Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome","volume":"77","author":"Glueck","year":"2002","journal-title":"Fertil Steril"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.071_bib44","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/humrep\/17.11.2858","article-title":"Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin","volume":"17","author":"Glueck","year":"2002","journal-title":"Hum Reprod Oxf Engl"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib45","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/s12884-020-03207-0","article-title":"Association of pregnancy outcomes in women with type 2 diabetes treated with metformin versus insulin when becoming pregnant","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Pregnancy Childbirth"},{"issue":"7908","key":"10.1016\/j.jaad.2024.11.071_bib46","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(75)91784-5","article-title":"Letter: birth defects and oestrogens and progesterones in pregnancy","volume":"1","author":"Harlap","year":"1975","journal-title":"Lancet Lond Engl"},{"issue":"7","key":"10.1016\/j.jaad.2024.11.071_bib47","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/ajmg.a.32608","article-title":"Genetic counseling for teratogenic risk due to exposure to medications: 89 pregnancies conceived during oral contraceptive use","volume":"149A","author":"Belli","year":"2009","journal-title":"Am J Med Genet A"},{"issue":"7","key":"10.1016\/j.jaad.2024.11.071_bib48","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1471-0528.1980.tb05001.x","article-title":"Oral contraception and congenital abnormalities","volume":"87","author":"Kasan","year":"1980","journal-title":"Br J Obstet Gynaecol"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1056\/NEJM197701132960202","article-title":"Cardiovascular birth defects and antenatal exposure to female sex hormones","volume":"296","author":"Heinonen","year":"1977","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/oxfordjournals.aje.a112977","article-title":"Oral contraceptives and birth defects","volume":"112","author":"Janerich","year":"1980","journal-title":"Am J Epidemiol"},{"issue":"14","key":"10.1016\/j.jaad.2024.11.071_bib51","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJM197410032911403","article-title":"Oral contraceptives and congenital limb-reduction defects","volume":"291","author":"Janerich","year":"1974","journal-title":"N Engl J Med"},{"issue":"8350","key":"10.1016\/j.jaad.2024.11.071_bib52","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(83)90705-5","article-title":"Congenital limb defects and the pill","volume":"2","author":"McCredie","year":"1983","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib53","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/0002-9378(86)90352-2","article-title":"Congenital limb reduction deformities and use of oral contraceptives","volume":"155","author":"Kricker","year":"1986","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib54","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/ije\/7.4.309","article-title":"Role of oral contraception in congenital malformations of offspring","volume":"7","author":"Bracken","year":"1978","journal-title":"Int J Epidemiol"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/tera.1420120305","article-title":"Prenatal exposure to oral contraceptives and transposition of the great vessels in man","volume":"12","author":"Yasuda","year":"1975","journal-title":"Teratology"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.071_bib56","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/adc.59.11.1052","article-title":"Maternal drug histories and central nervous system anomalies","volume":"59","author":"Winship","year":"1984","journal-title":"Arch Dis Child"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/tera.1420300308","article-title":"Cardiovascular birth defects and antenatal exposure to female sex hormones: a reevaluation of some base data","volume":"30","author":"Wiseman","year":"1984","journal-title":"Teratology"},{"issue":"22","key":"10.1016\/j.jaad.2024.11.071_bib58","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1001\/jama.1986.03370220090033","article-title":"Exogenous sex hormone exposure and the risk for major malformations","volume":"255","author":"Lammer","year":"1986","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib59","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/(SICI)1096-9926(199807)58:1<2::AID-TERA2>3.0.CO;2-4","article-title":"Corticosteroids during pregnancy and oral clefts: a case control study","volume":"58","author":"Rodr\u00edguez-Pinilla","year":"1998","journal-title":"Teratology"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib60","doi-asserted-by":"crossref","first-page":"585.e1","DOI":"10.1016\/j.ajog.2007.05.046","article-title":"Maternal corticosteroid use and orofacial clefts","volume":"197","author":"Carmichael","year":"2007","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib61","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/bdra.23248","article-title":"Corticosteroid use and risk of orofacial clefts","volume":"100","author":"Skuladottir","year":"2014","journal-title":"Birth Defects Res Clin Mol Teratol"},{"issue":"7","key":"10.1016\/j.jaad.2024.11.071_bib62","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1503\/cmaj.101063","article-title":"Corticosteroid use during pregnancy and risk of orofacial clefts","volume":"183","author":"Hviid","year":"2011","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib63","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0091-6749(86)80088-4","article-title":"Outcome of pregnancy in women requiring corticosteroids for severe asthma","volume":"78","author":"Fitzsimons","year":"1986","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib64","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/0002-9378(92)91596-3","article-title":"Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment","volume":"166","author":"Cowchock","year":"1992","journal-title":"Am J Obstet Gynecol"},{"issue":"4414","key":"10.1016\/j.jaad.2024.11.071_bib65","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1126\/science.482933","article-title":"Prednisone therapy and birth weight","volume":"206","author":"Smith","year":"1979","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib66","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00007890-199402270-00004","article-title":"National Transplatation Pregnancy Registry\u2013outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients","volume":"57","author":"Armenti","year":"1994","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib67","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S0041-1345(98)00408-4","article-title":"Pregnancy outcomes in female renal transplant recipients","volume":"30","author":"Armenti","year":"1998","journal-title":"Transpl Proc"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib68","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejogrb.2004.11.035","article-title":"Pregnancy outcome after renal allograft transplantation: 15 years experience","volume":"121","author":"Ghanem","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib69","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2016-209322","article-title":"Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib70","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","article-title":"A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database","volume":"36","author":"Carter","year":"2009","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223603","article-title":"Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study","volume":"14","author":"Chambers","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jaad.2024.11.071_bib72","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.40508","article-title":"Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database","volume":"70","author":"Clowse","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib73","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/art.38262","article-title":"Brief report: risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy","volume":"66","author":"Cooper","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.jaad.2024.11.071_bib74","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/apt.12936","article-title":"Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease","volume":"40","author":"Deepak","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib75","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40264-019-00881-8","article-title":"Exposure to infliximab during pregnancy: post-marketing experience","volume":"43","author":"Geldhof","year":"2020","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib76","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/ueg2.12236","article-title":"Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: a post hoc analysis","volume":"10","author":"Hart","year":"2022","journal-title":"United Eur Gastroenterol J"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib77","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/ibd\/izz110","article-title":"Anti-TNF therapy in pregnant women with inflammatory bowel disease: effects of therapeutic strategies on disease behavior and birth outcomes","volume":"26","author":"Julsgaard","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib78","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","article-title":"Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection","volume":"151","author":"Julsgaard","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib79","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000493462","article-title":"Pregnancy outcomes of patients exposed to adalimumab in Japan","volume":"37","author":"Kawai","year":"2019","journal-title":"Dig Dis"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib80","doi-asserted-by":"crossref","first-page":"139","DOI":"10.5217\/ir.2016.14.2.139","article-title":"Japanese study group for pregnant women with IBD. Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and\/or thiopurine therapy: a multicenter study from Japan","volume":"14","author":"Komoto","year":"2016","journal-title":"Intest Res"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.071_bib81","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/s41395-018-0202-9","article-title":"Pregnancy outcomes reported during the 13-year treat registry: a descriptive report","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib82","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib83","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/apt.16448","article-title":"Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and\/or anti-TNF: a French nationwide study 2010-2018","volume":"54","author":"Meyer","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib84","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/apt.15539","article-title":"Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study","volume":"51","author":"Moens","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jaad.2024.11.071_bib85","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/ibd.21583","article-title":"Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy","volume":"17","author":"Schnitzler","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib86","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/apt.12833","article-title":"Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease","volume":"40","author":"Seirafi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib87","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2010.140822","article-title":"Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register","volume":"70","author":"Verstappen","year":"2011","journal-title":"Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib88","first-page":"727","article-title":"Network of French pharmacovigilance centres","volume":"80","author":"Weber-Schoendorfer","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2024.11.071_bib89","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.reprotox.2013.11.004","article-title":"Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study","volume":"43","author":"Diav-Citrin","year":"2014","journal-title":"Reprod Toxicol"},{"issue":"12","key":"10.1016\/j.jaad.2024.11.071_bib90","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","article-title":"Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis","volume":"99","author":"Katz","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib91","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2015.08.039","article-title":"Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy","volume":"41","author":"Br\u00f6ms","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib92","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/bjd.16901","article-title":"Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database","volume":"179","author":"Warren","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib93","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/apt.16192","article-title":"Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study","volume":"53","author":"Wils","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib94","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib95","doi-asserted-by":"crossref","first-page":"98","DOI":"10.12891\/ceog3295.2017","article-title":"Pro-inflammatory and anti-inflammatory cytokine profiles in fetal growth restriction","volume":"44","author":"Al-Azemi","year":"2017","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib96","article-title":"Intrauterine growth restriction: cytokine profiles of trophoblast antigen-stimulated maternal lymphocytes","volume":"2012","author":"Raghupathy","year":"2011","journal-title":"Clin Dev Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib97","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib98","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/01.ftd.0000168294.25356.d0","article-title":"The safety of amoxicillin\/clavulanic acid and cefuroxime during lactation","volume":"27","author":"Benyamini","year":"2005","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib99","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2125.1988.tb03362.x","article-title":"Metronidazole excretion in human milk and its effect on the suckling neonate","volume":"26","author":"Passmore","year":"1988","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/bfm.2008.0135","article-title":"The safety of macrolides during lactation","volume":"4","author":"Goldstein","year":"2009","journal-title":"Breastfeed Med"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib101","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/0036554021000027010","article-title":"Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides","volume":"35","author":"S\u00f8rensen","year":"2003","journal-title":"Scand J Infect Dis"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib102","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/bjd.19710","article-title":"Guidelines for the management of hidradenitis suppurativa: recommendations supported by the Centre of Evidence of the French Society of Dermatology","volume":"184","author":"Bertolotti","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2024.11.071_bib103","series-title":"Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk","first-page":"588","author":"Briggs","year":"2012"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib104","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jdv.15332","article-title":"Rates of antibiotic resistance\/sensitivity in bacterial cultures of hidradenitis suppurativa patients","volume":"33","author":"Bettoli","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib105","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/01.AOG.0000216197.26783.b5","article-title":"Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks","volume":"107","author":"Nahum","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib106","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1542\/peds.108.3.776","article-title":"American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk","volume":"108","year":"2001","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib107","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s13555-022-00854-3","article-title":"Treatment of acne vulgaris during pregnancy and lactation: a narrative review","volume":"13","author":"Ly","year":"2023","journal-title":"Dermatol Ther Heidelb"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib108","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jpeds.2006.01.011","article-title":"Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome","volume":"148","author":"Glueck","year":"2006","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib109","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0010-7824(84)90001-5","article-title":"Effects of hormonal contraceptives on milk volume and infant growth. WHO special programme of research, development and research training in human reproduction task force on oral contraceptives","volume":"30","author":"Tankeyoon","year":"1984","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib110","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0010-7824(86)90054-5","article-title":"Long-term follow-up of children breast-fed by mothers using oral contraceptives","volume":"34","author":"Nilsson","year":"1986","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib111","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0010-7824(83)90053-7","article-title":"Fertility regulation in nursing women: V. Long-term influence of a low-dose combined oral contraceptive initiated at day 90 postpartum upon lactation and infant growth","volume":"27","author":"Peralta","year":"1983","journal-title":"Contraception"},{"issue":"e1-10","key":"10.1016\/j.jaad.2024.11.071_bib112","first-page":"427","article-title":"Safety of dermatologic medications in pregnancy and lactation: part II","volume":"417","author":"Butler","year":"2014","journal-title":"Lact J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib113","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib114","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.farma.2022.12.016","article-title":"Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases","volume":"47","author":"Barrueta","year":"2023","journal-title":"Farm Hosp"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib115","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","article-title":"Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development","volume":"155","author":"Matro","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib116","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/ijd.15286","article-title":"Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy","volume":"60","author":"Wohlmuth-Wieser","year":"2021","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib117","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000511284","article-title":"Rapid response to certolizumab pegol in hidradenitis suppurativa: a case report","volume":"7","author":"Esme","year":"2021","journal-title":"Skin Appendage Disord"},{"issue":"Suppl 3","key":"10.1016\/j.jaad.2024.11.071_bib118","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1542\/peds.2013-0490B","article-title":"Evidence-based recommendations for the diagnosis and treatment of pediatric acne","volume":"131","author":"Eichenfield","year":"2013","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib119","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1525-1470.2012.01811.x","article-title":"Tretinoin microsphere gel 0.04% pump for treating acne vulgaris in preadolescents: a randomized, controlled study","volume":"29","author":"Eichenfield","year":"2012","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1525-1470.2008.00688.x","article-title":"Adapalene gel 0.1% in the treatment of infantile acne: an open clinical study","volume":"25","author":"Kose","year":"2008","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib121","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4103\/0253-7613.89815","article-title":"Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: a randomized controlled trial","volume":"43","author":"Choudhury","year":"2011","journal-title":"Indian J Pharmacol"},{"issue":"5 Suppl 1","key":"10.1016\/j.jaad.2024.11.071_bib122","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jaad.2015.07.048","article-title":"Local wound care and topical management of hidradenitis suppurativa","volume":"73","author":"Alavi","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib123","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1473-3099(15)00527-7","article-title":"Systematic review of antibiotic resistance in acne: an increasing topical and oral threat","volume":"16","author":"Walsh","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib124","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaad.2018.10.063","article-title":"The effect of antimicrobial washes on antibacterial resistance in hidradenitis suppurativa","volume":"80","author":"Leiphart","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib125","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00403-020-02053-6","article-title":"Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients","volume":"312","author":"Riis","year":"2020","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib126","article-title":"Review of current immunologic therapies for hidradenitis suppurativa","volume":"2017","author":"Shanmugam","year":"2017","journal-title":"Int J Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib127","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/13543784.2018.1412430","article-title":"Investigational drugs in clinical trials for hidradenitis suppurativa","volume":"27","author":"Riis","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib128","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jpeds.2015.02.015","article-title":"No visible dental staining in children treated with doxycycline for suspected rocky mountain spotted fever","volume":"166","author":"Todd","year":"2015","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0009922806290026","article-title":"Absence of tooth staining with doxycycline treatment in young children","volume":"46","author":"Volovitz","year":"2007","journal-title":"Clin Pediatr (Phila)"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib130","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1542\/peds.108.2.519","article-title":"Minocycline and Pseudotumor cerebri: the well-known but well-kept secret","volume":"108","author":"Weese-Mayer","year":"2001","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib131","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jdv.12127","article-title":"Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients","volume":"28","author":"Bettoli","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib132","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1515\/JPEM.2008.21.4.339","article-title":"Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial","volume":"21","author":"Atabek","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib133","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1399-5448.2008.00434.x","article-title":"Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance","volume":"9","author":"Burgert","year":"2008","journal-title":"Pediatr Diabetes"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib134","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jpeds.2008.01.018","article-title":"Addition of metformin to a lifestyle modification program in adolescents with insulin resistance","volume":"152","author":"Love-Osborne","year":"2008","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib135","doi-asserted-by":"crossref","DOI":"10.1515\/ijamh-2015-0110","article-title":"Metformin effectiveness and safety in the management of overweight\/obese nondiabetic children and adolescents: metabolic benefits of the continuous exposure to metformin at 12 and 24 months","volume":"29","author":"Marques","year":"2016","journal-title":"Int J Adolesc Med Health"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib136","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2337\/diacare.25.1.89","article-title":"Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial","volume":"25","author":"Jones","year":"2002","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib137","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s13340-018-0361-3","article-title":"Metformin monotherapy in children and adolescents with type 2 diabetes mellitus in Japan","volume":"10","author":"Matsuura","year":"2018","journal-title":"Diabetol Int"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib138","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/pde.14391","article-title":"Use of spironolactone to treat acne in adolescent females","volume":"38","author":"Roberts","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2024.11.071_bib139","first-page":"704","article-title":"Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients","volume":"55","author":"Shefrin","year":"2009","journal-title":"Can Fam Physician"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib140","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2016.06.001","article-title":"Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa","volume":"75","author":"Wong","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib141","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0190-9622(96)90281-9","article-title":"Cyclosporine in severe childhood atopic dermatitis: a multicenter study","volume":"34","author":"Berth-Jones","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib142","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1542\/peds.2007-2232","article-title":"Management of atopic dermatitis in the pediatric population","volume":"122","author":"Krakowski","year":"2008","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib143","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2010.06.040","article-title":"Effective monitoring of isotretinoin safety in a pediatric dermatology population: a novel patient symptom survey approach","volume":"65","author":"Hodgkiss-Harlow","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib144","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jaad.2010.09.017","article-title":"The impact of the iPLEDGE program on isotretinoin feal exposure in. an integrated health care system","volume":"65","author":"Shin","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"2 Suppl 1","key":"10.1016\/j.jaad.2024.11.071_bib145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1590\/abd1806-4841.20198607","article-title":"Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology","volume":"94","author":"Magalh\u00e3es","year":"2019","journal-title":"An Bras Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2024.11.071_bib146","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S2468-1253(21)00142-4","article-title":"Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study","volume":"6","author":"Croft","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib147","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/MIB.0000000000000715","article-title":"Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease","volume":"22","author":"Dubinsky","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2024.11.071_bib148","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpeds.2018.05.042","article-title":"Safety of adalimumab in pediatric patients with Polyarticular Juvenile Idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohn's disease","volume":"201","author":"Horneff","year":"2018","journal-title":"J Pediatr"},{"issue":"10089","key":"10.1016\/j.jaad.2024.11.071_bib149","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib150","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/bjd.18029","article-title":"Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study","volume":"181","author":"Tha\u00e7i","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib151","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1089\/jop.2020.0081","article-title":"Anti-tumor necrosis factor treatment in the management of pediatric noninfectious uveitis: infliximab versus adalimumab","volume":"37","author":"Gunduz","year":"2021","journal-title":"J Ocul Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.jaad.2024.11.071_bib152","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3899\/jrheum.131231","article-title":"Infliximab in pediatric rheumatology patients: a retrospective analysis of infusion reactions and severe adverse events during 2246 infusions over 12 years","volume":"41","author":"Aeschlimann","year":"2014","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib153","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/MEG.0b013e32835159f2","article-title":"The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease","volume":"24","author":"Kierkus","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib154","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MPG.0000000000000684","article-title":"Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease","volume":"50","author":"Kierku\u015b","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib155","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib156","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00228-019-02715-z","article-title":"Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients-a case-control study","volume":"75","author":"Wassenaer","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib157","first-page":"373","article-title":"Safety of infliximab treatment in pediatric patients with inflammatory bowel disease","volume":"39","author":"Friesen","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib158","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jdv.17002","article-title":"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial","volume":"35","author":"Bodemer","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2024.11.071_bib159","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1007\/s00520-020-05972-2","article-title":"Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study","volume":"29","author":"Raimondi","year":"2021","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib160","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00520-010-0988-5","article-title":"Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)","volume":"19","author":"Jatoi","year":"2011","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib161","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jaad.2016.01.019","article-title":"Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: a randomized, open-label trial","volume":"74","author":"Deplanque","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.071_bib162","first-page":"6175","article-title":"Prophylactic effect of oral minocycline in combination with topical steroid and skin care against panitumumab-induced acneiform rash in metastatic colorectal cancer patients","volume":"35","author":"Yamada","year":"2015","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib163","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3109\/10428194.2012.725848","article-title":"Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies","volume":"54","author":"Shinohara","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.071_bib164","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/1097-0142(19930601)71:11<3640::AID-CNCR2820711128>3.0.CO;2-H","article-title":"Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer","volume":"71","author":"Rubenstein","year":"1993","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib165","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s15010-015-0784-8","article-title":"Ertapenem usage in cancer patients with and without neutropenia: a report on 97 cases from a comprehensive cancer center","volume":"43","author":"Nesher","year":"2015","journal-title":"Infection"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib166","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1245\/s10434-013-3294-x","article-title":"Perioperative antimicrobial prophylaxis for intra-abdominal surgery in patients with cancer: a retrospective study comparing ertapenem and nonertapenem antibiotics","volume":"21","author":"Mahajan","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib167","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/JCO.1995.13.1.239","article-title":"Ciprofloxacin versus trimethoprim\/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial","volume":"13","author":"Lew","year":"1995","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2024.11.071_bib168","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1200\/JCO.2012.45.8109","volume":"31","author":"Kern","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib169","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/0002-9343(83)90785-4","article-title":"Double-blind randomized study of prophylactic trimethoprim\/sulfamethoxazole in granulocytopenic patients with hematologic malignancies","volume":"74","author":"Gualtieri","year":"1983","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib170","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jac\/15.3.353","article-title":"Ceftazidime plus mezlocillin as initial antibiotic therapy in febrile neutropenic patients with haematological malignancy","volume":"15","author":"Clough","year":"1985","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.jaad.2024.11.071_bib171","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1002\/cncr.21089","article-title":"Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin","volume":"103","author":"Chamilos","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2024.11.071_bib172","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1186\/s12885-016-2658-6","article-title":"Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer","volume":"16","author":"Arrieta","year":"2016","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib173","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/1055-9965.EPI-14-0056","article-title":"The use of metformin in patients with prostate cancer and the risk of death","volume":"23","author":"Bensimon","year":"2014","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib174","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/dc11-1313","article-title":"Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival","volume":"35","author":"Currie","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib175","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.29.02.06.dc05-1558","article-title":"Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin","volume":"29","author":"Bowker","year":"2006","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.jaad.2024.11.071_bib176","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/bjc.2012.71","article-title":"Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer","volume":"106","author":"Garrett","year":"2012","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib177","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10549-012-2404-y","article-title":"Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes","volume":"137","author":"Hou","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"10.1016\/j.jaad.2024.11.071_bib178","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","article-title":"Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer","volume":"27","author":"Jiralerspong","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2024.11.071_bib179","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lungcan.2020.11.011","article-title":"Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer","volume":"151","author":"Lee","year":"2021","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib180","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.2337\/dc12-2535","article-title":"Association between metformin therapy and mortality after breast cancer: a population-based study","volume":"36","author":"Lega","year":"2013","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib181","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00280-019-03967-3","article-title":"A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors","volume":"84","author":"Saif","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaad.2024.11.071_bib182","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejogrb.2016.06.013","article-title":"The prognostic role of metformin in patients with endometrial cancer: a retrospective study","volume":"203","author":"Seebacher","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"7","key":"10.1016\/j.jaad.2024.11.071_bib183","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1470-2045(15)00027-3","article-title":"Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial","volume":"16","author":"Kordes","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib184","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0090-4295(99)80021-1","article-title":"Treatment with finasteride following radical prostatectomy for prostate cancer","volume":"45","author":"Andriole","year":"1995","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib185","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.juro.2016.08.006","article-title":"Suppressed recurrent bladder cancer after androgen suppression with androgen deprivation therapy or 5\u03b1-reductase inhibitor","volume":"197","author":"Shiota","year":"2017","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib186","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.juro.2018.04.082","article-title":"Bladder cancer survival of men receiving 5\u03b1-reductase inhibitors","volume":"200","author":"M\u00e4kel\u00e4","year":"2018","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib187","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2020.05.081","article-title":"Spironolactone use does not increase the risk of female breast cancer recurrence: a retrospective analysis","volume":"83","author":"Wei","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.11.071_bib188","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejogrb.2020.12.035","article-title":"Breast cancer recurrence risk after hormonal contraceptive use in survivors of reproductive age","volume":"258","author":"Ostroot","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"9","key":"10.1016\/j.jaad.2024.11.071_bib189","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","article-title":"Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer","volume":"63","author":"Beaugerie","year":"2014","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.071_bib190","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaad.2024.11.071_bib191","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103012","article-title":"Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting - a systematic review and meta-analysis","volume":"152","author":"Raghunath","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib192","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/SLA.0b013e3181fc9d36","article-title":"Effects of chronic immunosuppression on long-term oncologic outcomes for colorectal cancer patients undergoing surgery","volume":"253","author":"Khoury","year":"2011","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib193","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","article-title":"Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents","volume":"14","author":"Axelrad","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib194","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/art.39738","article-title":"Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study","volume":"68","author":"Mamtani","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.jaad.2024.11.071_bib195","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJM199009203231205","article-title":"Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck","volume":"323","author":"Hong","year":"1990","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib196","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archotol.131.3.198","article-title":"Chemoprevention of head and neck cancer with retinoids: a negative result","volume":"131","author":"Perry","year":"2005","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib197","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1440-0960.2002.00613.x","article-title":"Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients","volume":"43","author":"George","year":"2002","journal-title":"Australas J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2024.11.071_bib198","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/cncr.26374","article-title":"Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)","volume":"118","author":"Kadakia","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib199","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.jaad.2024.11.071_bib200","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1136\/annrheumdis-2014-205745","article-title":"TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study","volume":"74","author":"Raaschou","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.071_bib201","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/rheumatology\/kew314","article-title":"The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis","volume":"55","author":"Silva-Fern\u00e1ndez","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib202","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/annrheumdis-2017-212086","article-title":"Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study","volume":"77","author":"Dreyer","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib203","doi-asserted-by":"crossref","first-page":"291","DOI":"10.7326\/M17-2812","article-title":"Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: a nationwide population-based cohort study","volume":"169","author":"Raaschou","year":"2018","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib204","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/jgh.15806","article-title":"Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy","volume":"37","author":"Hasan","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib205","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cgh.2020.10.007","article-title":"Vedolizumab or tumor necrosis factor antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: a retrospective cohort study","volume":"20","author":"Vedamurthy","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib206","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib207","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/CMR.0000000000000284","article-title":"Melanoma risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors: a systematic review and meta-analysis","volume":"26","author":"Olsen","year":"2016","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib208","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.20129","article-title":"Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register","volume":"62","author":"Dixon","year":"2010","journal-title":"Arthritis Care Res Hoboken"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib209","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.cgh.2023.01.002","article-title":"Comparative safety of biologic agents in patients with inflammatory bowel disease with active or recent malignancy: a multi-center cohort study","volume":"21","author":"Holmer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib210","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/ecco-jcc\/jjac061","article-title":"Comparative risk of incident cancer in patients with inflammatory bowel disease with prior non-digestive malignancy according to immunomodulator: a multicentre cohort study","volume":"16","author":"Poullenot","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaad.2024.11.071_bib211","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"46","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.jaad.2024.11.071_bib212","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00384-015-2344-1","article-title":"Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma\u2013challenges in management","volume":"30","author":"Lee","year":"2015","journal-title":"Int J Colorectal Dis"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.071_bib213","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s13555-022-00797-9","article-title":"Secukinumab in patients with psoriasis and a personal history of malignancy: a multicenter real-life observational study","volume":"12","author":"Pellegrini","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"10.1016\/j.jaad.2024.11.071_bib214","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ibd\/izac035","article-title":"Ustekinumab and vedolizumab are not associated with subsequent cancer in IBD patients with prior malignancy","volume":"28","author":"Hong","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib215","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib216","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial","volume":"149","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib217","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib218","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(19)30575-4","volume":"20","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib219","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10096-012-1788-2","article-title":"Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection","volume":"32","author":"Pina","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"17","key":"10.1016\/j.jaad.2024.11.071_bib220","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","article-title":"Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study","volume":"166","author":"Page","year":"2006","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib221","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02048-2019","article-title":"Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs","volume":"55","author":"Ronald","year":"2020","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib222","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/M19-3741","article-title":"Health system costs of treating latent tuberculosis infection with four months of rifampin versus nine months of isoniazid in different settings","volume":"173","author":"Bastos","year":"2020","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib223","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10067-021-05969-0","article-title":"Safety of latent tuberculosis infection treatment in older patients with immune-mediated inflammatory diseases","volume":"41","author":"Chung","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.071_bib224","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/resp.13338","article-title":"Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes","volume":"23","author":"Lin","year":"2018","journal-title":"Respirology"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205807","article-title":"Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: a nationwide cohort study with validated diagnostic criteria","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib226","doi-asserted-by":"crossref","first-page":"e1252","DOI":"10.1093\/cid\/ciab209","article-title":"Completion rate and safety of programmatic screening and treatment for latent tuberculosis infection in elderly patients with poorly controlled diabetic mellitus: a prospective multicenter study","volume":"73","author":"Huang","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib227","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01695-2018","article-title":"Reduced prevalence of latent tuberculosis infection in diabetes patients using metformin and statins","volume":"53","author":"Magee","year":"2019","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.jaad.2024.11.071_bib228","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1055\/s-0034-1377044","article-title":"Latent tuberculosis in patients with diabetes mellitus: prevalence, progression and public health implications","volume":"122","author":"Leow","year":"2014","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib229","doi-asserted-by":"crossref","first-page":"573","DOI":"10.5588\/ijtld.12.0920","article-title":"Active case finding for tuberculosis among high-risk groups in low-incidence countries","volume":"17","author":"Zenner","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib230","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib231","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease","volume":"104","author":"Marehbian","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib232","first-page":"80","article-title":"High risk of activation of latent tuberculosis infection in rheumatic disease patients","volume":"52","author":"Long","year":"2020","journal-title":"Infect Lond"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib233","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jaad.2024.11.071_bib234","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib235","article-title":"QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jaad.2024.11.071_bib236","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.3899\/jrheum.130303","article-title":"Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-\u03b3 release assay results","volume":"40","author":"Costantino","year":"2013","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.071_bib237","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/annrheumdis-2011-200408","article-title":"Influence of replacing tuberculin skin test with ex\u00a0vivo interferon \u03b3 release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy","volume":"71","author":"Mariette","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib238","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1007\/s10620-018-5178-1","article-title":"A study of optimal screening for latent tuberculosis in patients with inflammatory bowel disease","volume":"63","author":"Al-Taweel","year":"2018","journal-title":"Dig Sci"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib239","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib240","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1128\/CVI.00049-13","article-title":"High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy","volume":"20","author":"He","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"8","key":"10.1016\/j.jaad.2024.11.071_bib241","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2017.34","article-title":"Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections","volume":"6","author":"Kamm\u00fcller","year":"2017","journal-title":"Clin Transl Immunology"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib242","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","article-title":"Treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis","volume":"157","author":"Elewski","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib243","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1365-2133.2012.11142.x","article-title":"The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection","volume":"167","author":"Tsai","year":"2012","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib244","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jhep.2008.01.024","article-title":"Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study","volume":"48","author":"Terg","year":"2008","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jaad.2024.11.071_bib245","doi-asserted-by":"crossref","first-page":"595","DOI":"10.7326\/0003-4819-122-8-199504150-00007","article-title":"Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial","volume":"122","author":"Singh","year":"1995","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib246","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S1665-2681(19)31682-5","article-title":"Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?","volume":"9","author":"Nader","year":"2010","journal-title":"Ann Hepatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib247","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0873-2159(15)30040-4","article-title":"Adverse reactions to antituberculosis drugs in in-hospital patients: severity and risk factors","volume":"16","author":"Vilari\u00e7a","year":"2010","journal-title":"Rev Port Pneumol"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib248","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100745","article-title":"Randomised controlled trial: effect of metformin add-on therapy on functional cure in entecavir-treated patients with chronic hepatitis B","volume":"27","author":"Zhang","year":"2022","journal-title":"Ann Hepatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib249","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/hep.23206","article-title":"Treatment of insulin resistance with metformin in na\u00efve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin","volume":"50","author":"Romero-G\u00f3mez","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib250","article-title":"The potential hepatoprotective effect of metformin in hepatitis C virus-infected adolescent patients with beta thalassemia major: randomised clinical trial","volume":"75","author":"Monem","year":"2021","journal-title":"Int J Clin Pr"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib251","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1016\/j.ijid.2012.02.004","article-title":"The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance","volume":"16","author":"Yu","year":"2012","journal-title":"Int J Infect Dis"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.071_bib252","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1007\/s10620-022-07454-3","article-title":"Incidence of, risk factors for, and outcomes after ascites in a population-based cohort of older Americans","volume":"67","author":"Tapper","year":"2022","journal-title":"Dig Sci"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib253","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.352","article-title":"Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment","volume":"4","author":"Yip","year":"2021","journal-title":"Health Sci Rep"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib254","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jhep.2022.09.019","article-title":"Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan","volume":"78","author":"Tsai","year":"2023","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jaad.2024.11.071_bib255","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1210\/jc.2010-2415","article-title":"Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients","volume":"96","author":"Nkontchou","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"10.1016\/j.jaad.2024.11.071_bib256","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.3748\/wjg.v16.i24.3025","article-title":"Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma","volume":"16","author":"Donadon","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib257","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1478-3231.2010.02223.x","article-title":"Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease","volume":"30","author":"Donadon","year":"2010","journal-title":"Liver Int"},{"issue":"20","key":"10.1016\/j.jaad.2024.11.071_bib258","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.3748\/wjg.15.2506","article-title":"Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease","volume":"15","author":"Donadon","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib259","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/1099-1557(200005\/06)9:3<245::AID-PDS500>3.0.CO;2-7","article-title":"Safety of hormonal steroid contraceptive use for hepatitis B virus carrier women","volume":"9","author":"Wang","year":"2000","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib260","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep.20463","article-title":"Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure","volume":"40","author":"Martino","year":"2004","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.071_bib261","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/jdv.14146","article-title":"Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature","volume":"31","author":"Piaserico","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib262","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","article-title":"Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature","volume":"77","author":"Snast","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib263","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0196210","article-title":"Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections","volume":"13","author":"Chiu","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib264","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-014-0214-x","article-title":"Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis","volume":"14","author":"Morisco","year":"2014","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib265","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.12045","article-title":"Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting","volume":"168","author":"Navarro","year":"2013","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib266","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.transproceed.2004.11.041","article-title":"Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease","volume":"37","author":"Inoue","year":"2005","journal-title":"Transpl Proc"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib267","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00535-002-1104-5","article-title":"Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial","volume":"38","author":"Inoue","year":"2003","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib268","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.transproceed.2008.10.056","article-title":"Efficacy of interferon Beta combined with cyclosporine induction and intensified therapy for retreatment of chronic hepatitis C","volume":"41","author":"Inoue","year":"2009","journal-title":"Transpl Proc"},{"key":"10.1016\/j.jaad.2024.11.071_bib269","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1196\/annals.1423.058","article-title":"Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection","volume":"1110","author":"Galeazzi","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib270","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jaad.2018.05.004","article-title":"Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: real-world data from a nationwide cohort study in Taiwan","volume":"79","author":"Tang","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib271","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s13075-018-1748-z","article-title":"Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study","volume":"20","author":"Tien","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib272","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.20130","article-title":"Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative\/anti-hepatitis B core antigen positive) with rheumatic diseases","volume":"62","author":"Caporali","year":"2010","journal-title":"Arthritis Care Res Hoboken"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib273","doi-asserted-by":"crossref","first-page":"567","DOI":"10.5009\/gnl210204","article-title":"Risk of reactivation in patients with immune-mediated inflammatory diseases receiving biologics: focus on the timing of biologics after anti-HBV treatment","volume":"16","author":"Ahn","year":"2022","journal-title":"Gut Liver"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib274","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00535-010-0367-5","article-title":"Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts","volume":"46","author":"Tamori","year":"2011","journal-title":"J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib275","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3109\/s10165-011-0458-z","article-title":"Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and\/or nonbiological disease-modifying antirheumatic drugs","volume":"21","author":"Mori","year":"2011","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib276","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13075-019-2053-1","article-title":"Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital","volume":"21","author":"Fukuda","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib277","first-page":"102","article-title":"Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study","volume":"36","author":"Papalopoulos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib278","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/1756-185X.14034","article-title":"Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-\u03b1 therapy","volume":"24","author":"Fidan","year":"2021","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib279","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1136\/ard.2010.148783","article-title":"Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy","volume":"70","author":"Lan","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib280","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hep.27716","article-title":"Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection","volume":"62","author":"Barone","year":"2015","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jaad.2024.11.071_bib281","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-018-0671-z","article-title":"Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab","volume":"38","author":"Ting","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib282","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/1756-185X.12359","article-title":"Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs","volume":"19","author":"Nakamura","year":"2016","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib283","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/s10165-010-0337-z","article-title":"Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients","volume":"21","author":"Urata","year":"2011","journal-title":"Mod Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib284","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2868","article-title":"Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients","volume":"11","author":"Charpin","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.jaad.2024.11.071_bib285","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.cgh.2018.04.033","article-title":"Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists","volume":"16","author":"Pauly","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib286","first-page":"285","article-title":"Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease","volume":"25","author":"Cassano","year":"2011","journal-title":"J Biol Regul Homeost Agents"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib287","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/1756-185X.13401","article-title":"Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs","volume":"22","author":"Watanabe","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib288","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/OLQ.0000000000000216","article-title":"Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high risk sex: a randomized, controlled pilot study","volume":"42","author":"Bolan","year":"2015","journal-title":"Sex Transm Dis"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib289","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1214901","article-title":"A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa","volume":"370","author":"Bwakura-Dangarembizi","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jaad.2024.11.071_bib290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206907","article-title":"Discontinuing cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in Uganda (COSTOP): a randomised placebo controlled trial","volume":"13","author":"Anywaine","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.071_bib291","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archinte.1996.00440020081010","article-title":"A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens","volume":"156","author":"Ioannidis","year":"1996","journal-title":"Arch Intern Med"},{"issue":"26","key":"10.1016\/j.jaad.2024.11.071_bib292","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJM199812243392604","article-title":"Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group","volume":"339","author":"El-Sadr","year":"1998","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaad.2024.11.071_bib293","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1128\/AAC.01598-10","article-title":"Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets","volume":"55","author":"Decloedt","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib294","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/jac\/dkz557","article-title":"Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial","volume":"75","author":"Atwine","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.jaad.2024.11.071_bib295","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa338","article-title":"Repurposing metformin in nondiabetic people with HIV: influence on weight and gut microbiota","volume":"7","author":"Isnard","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib296","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00002030-200402200-00013","article-title":"Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients","volume":"18","author":"Driscoll","year":"2004","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib297","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/QAD.0b013e328011220e","article-title":"Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist\/hip ratio","volume":"21","author":"Mulligan","year":"2007","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib298","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-143-5-200509060-00009","article-title":"Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial","volume":"143","author":"van Wijk","year":"2005","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.071_bib299","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1089\/aid.2022.0129","article-title":"Association between metformin use and cognitive and physical function in persons with HIV and diabetes","volume":"39","author":"Masters","year":"2023","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib300","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/QAD.0b013e32834f33cc","article-title":"Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome","volume":"26","author":"Fitch","year":"2012","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib301","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.cjca.2018.12.020","article-title":"Getting to the heart of the matter: a review of drug interactions between HIV antiretrovirals and cardiology medications","volume":"35","author":"Gigu\u00e8re","year":"2019","journal-title":"Can J Cardiol"},{"issue":"3Suppl 2","key":"10.1016\/j.jaad.2024.11.071_bib302","article-title":"Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices","volume":"19","author":"Radix","year":"2016","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.071_bib303","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00002030-200102160-00004","article-title":"Placebo-controlled trial of prednisone in advanced HIV-1 infection","volume":"15","author":"McComsey","year":"2001","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.071_bib304","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00126334-200305010-00007","article-title":"Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1","volume":"33","author":"Montaner","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib305","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.cgh.2020.12.023","article-title":"Impact of HIV infection on the course of inflammatory bowel disease and drug safety profile: a multicenter GETAID study","volume":"20","author":"Guillo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2024.11.071_bib306","series-title":"Proceedings of the American Academy of Dermatology Annual Meeting; New Orleans, LA, USA","first-page":"17","article-title":"Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa: 48-week efficacy and safety from BE HEARD I & II, two phase 3, randomized, double-blind, placebo-controlled, multicenter studies","author":"Kimball","year":"2023"},{"issue":"10378","key":"10.1016\/j.jaad.2024.11.071_bib307","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jaad.2024.11.071_bib308","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/exd.14619","article-title":"IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: combined results from a pre-clinical and phase II proof-of-concept study","volume":"31","author":"Kimball","year":"2022","journal-title":"Exp Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2024.11.071_bib309","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jid.2019.10.024","article-title":"A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain","volume":"140","author":"Gottlieb","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2024.11.071_bib310","first-page":"3497","author":"Kimball","year":"2022"},{"key":"10.1016\/j.jaad.2024.11.071_bib313","series-title":"Proceedings from the American Academy of Dermatology Annual Meeting. New Orleans, LA, USA","first-page":"17","article-title":"Spesolimab for hidradenitis suppurativa: a proof-of-concept study","author":"Alavi","year":"2023"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.071_bib314","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.071_bib315","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting il-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.071_bib316","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224033954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224033954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:12:45Z","timestamp":1742357565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224033954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":314,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0190962224033954"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.11.071","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.11.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}